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Abstract
The natural history of type-speciﬁc oral infection of human
papillomavirus (HPV) was assessed in a cohort of HIV-infected
men (538 men who have sex with men (MSM); 195 heterosexuals).
Risk factors associated with oral HPV infections were examined.
The overall prevalence of HPV was 16%: HPV-16 was the most
prevalent type (3.7% MSM; 7.8% heterosexuals). The prevalence of
HPV-16 in heterosexuals was associated with CD4 nadir counts
<200 cells/lL (ORadjusted = 3.0, 95% CI, 1.4–6.3). The overall
incidence of HPV was similar between groups (11%), but the
incidence of HPV-16 was higher in heterosexuals
(ORadjusted = 3.2, 95% CI, 1.1–9.5). Not only MSM but also
HIV-infected heterosexual men are at risk of HPV infection.
Regular and careful oral inspection is needed.
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High-risk (HR) or oncogenic human papillomavirus (HPV)
types are the most common types related to the development
of anogenital squamous cell cancers [1]. However, there is
growing evidence that oral HR-HPV infections, principally
HPV-16, contribute to the risk of oral or oropharyngeal
squamous cell carcinomas (OSCCs) [2]. Initial studies indicate
that oral HPV infection is associated with sexual behaviour and
immunosuppression, and the incidence of OSCC related to
HPV has signiﬁcantly increased in the male population [3]. In
patients infected with human immunodeﬁciency virus (HIV),
oral HPV infections seem to persist for longer than in the
healthy population [4], increasing the risk of developing
oropharyngeal cancer [5].
Most of the information available about oral HPV infection
is based on women and men who have sex with men (MSM)
with or without HIV infection [6,7] and on healthy young men
[8,9]. However, data reported on heterosexual HIV-infected
men are scarce [10,11]. The purpose of this study is to
present data on the prevalence, evolution (clearance and
incidence) and risk factors associated with type-speciﬁc HPV
infections in the oral mucosa of MSM and heterosexual
HIV-infected men.
Overall data about oral HPV infection were previously
reported in the single-centre prospective CARHMEN cohort
[12] of the Hospital Germans Trias i Pujol (Badalona, Spain).
The cohort is comprised of 733 patients (538 MSM and 195
heterosexual men) with a median age of 41 years, recruited
from January 2005 to May 2009. Patients were screened
annually for anal, penile and oral HPV infections. The median
(interquartile range) follow-up time was 24 (12–36) months.
Oral samples were obtained by oral brush/rinse [12]. DNA
was extracted using the QIAamp Viral DNA kit (QIAGEN,
Hilden, Germany) and HPV typing performed by the F-HPV
typingTM multiplex PCR (Molgentix SL, Barcelona, Spain) [12].
The assay permits the detection of 13 HR-genotypes
(16,18,31,33,35,39,45,51,52,56,58,59 and 68) and two low-risk
(LR) genotypes (6 and 11) .
Differences between groups were evaluated using the
chi-squared test; for prevalence, odds ratios (ORs) with their
95% conﬁdence intervals (CIs) were calculated. Multivariate
regression models were adjusted to different covariates
(sexual behaviour; age; years of HIV infection; nadir and basal
CD4 counts; time on HAART; tobacco, alcohol and intrave-
nous drug use; and number of sexual partners). Clearance and
incidence of HPV infection were analyzed by the Kaplan–Meier
method, and differences using the Mantel-Haenzel log-rank
test. Clearance and incidence rates were calculated based on a
denominator of 1000 person-years. p ≤ 0.05 was considered
statistically signiﬁcant. Data were analyzed using SPSS version
15.0 (SPSS Inc., Chicago, IL, USA).
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The baseline characteristics of the CARHMEN cohort have
been previously published [12]. Brieﬂy, the MSM population
had a shorter time from HIV diagnosis to enrollment (median
of years, 7 vs. 15) and a lower percentage of AIDS diagnosis
(14 vs. 22); whereas the heterosexual group had a poorer
disease status than MSM, namely lower nadir (139 vs. 280 cells/
lL) and baseline (457 vs. 517 cells/lL) CD4 counts (p <0.001).
No patient presented with or had a history of oral precan-
cerous lesions or OSCC during the study.
The prevalence of oral HPV at baseline in the overall cohort
was 16% (107/650): 16% (71/458) MSM and 19% (36/192)
heterosexuals. Similar percentages of single infection (11.6%
MSM; 15.1% heterosexuals), dual infection (2.8% MSM; 2.6%
heterosexuals) and multiple >2 types (1.1% MSM; 1.0% hetero-
sexuals) of infection were observed between groups [12].
The most prevalent HPV-genotype in both groups was
HPV-16: 3.7% (17/458) in MSM and 7.8% (15/192) in hetero-
sexuals (Fig. 1). Heterosexual men presented a greater
prevalence of oral HPV-16 infection than MSM, but this higher
prevalence was directly associated with low CD4 nadir counts
(<200 cells/lL) (OR = 3.0, 95% CI, 1.4–6.3) (Table 2).
The clearance of oral HPV infection was 44% (39/89) in the
overall population: 48% (29/60) in MSM and 34% (10/29) in
heterosexuals. However, the rate of clearance for HPV-39 was
higher in heterosexuals, with a lower mean retention time
(26.2 months) compared with MSM (41.4 months) (Table 1).
The cumulative incidence of HPV infection for the cohort
was 11% (49/451): 11% (36/333) in MSM and 11% (13/11) in
heterosexuals. The incidence of oral HPV-16 infection was
higher in the heterosexuals and the time of incidence was
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FIG. 1. Percentage of HPV-type speciﬁc infections in the mouths of HIV-infected men at baseline and the last follow-up visits. Statistically signiﬁcant
differences between groups are represented by an asterisk (p <0.05, bivariate model).
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shorter than in MSM (p <0.05) (Table 1). This higher risk of
incident oral HPV-16 infections in the heterosexuals was
supported by the adjusted model (OR = 3.2, 95% CI, 1.1–9.5)
(Table 2).
Most studies on HPV infections are carried out in high-risk
populations such as sex workers, women and MSM [13,14].
However, little is known about oral HPV infections in
heterosexual HIV-infected men. Our heterosexual population
was a sexually active group (95% were not monogamous) and
their immunological status was much poorer than that of MSM
[12]. This condition was reﬂected in the results of the
multivariate model, where the prevalence of oral HPV-16 was
directly associated with the nadir CD4 counts instead of the
sexual condition. It is known that immunosuppression may
contribute to increased persistence or progression of oral
HPV infection [6].
In healthy men, the cumulative incidence of HPV-16 has
been described to be around 0.008 infections per year [15];
whereas in HIV-infected men we have observed an incidence
of 0.008 per month in MSM and 2.2 per month in heterosex-
uals, indicating a great risk of oral HPV-16 infection in
HIV-infected heterosexual patients, as previously suggested
[11]. As described by other authors [15,16], the risk of
acquiring oral HPV is higher when performing oral sex on a
women than a man; in consequence, HIV+ heterosexual men
may be at greater risk of developing HPV-related oral cancer.
This study has some limitations. The deﬁned clearance
terms may be overestimated for patients with only one sample
TABLE 1. Type-speciﬁc clearance and incidence of oral HPV infections in MSM and heterosexual HIV-infected men in the
CARHMEN cohort
Type
Cleared oral infections
Men who have sex with men (n = 60) Heterosexual men (n = 29)
No. Clearance ratea (95% CI) Mean retention timec (months) No. Clearance ratea (95% CI) Mean retention timec (months)
Low risk
HPV-6 4 14.3 (3.9–36.7) 38.5 (30.6–46.6) 2 28.2 (3.4-ND) 23.6 (11.2–36.1)
HPV-11 1 23.8 (0.6-ND) ND 1 76.9 (ND) ND
High risk
HPV-16 11 18.9 (9.4–33.8) 42.3 (37.2–47.4) 3 7.6 (1.5–22.1) 48.3 (41.5–55.1)
HPV-18 0 0.0 ND 0 0.0 ND
HPV-31 1 26.3 (0.6-ND) 38 (ND) 1 40.0 (ND) 25 (ND)
HPV-33 8 26.8 (11.6–52.9) ND 0 0.0 ND
HPV-35 2 12.6 (1.5–45.4) ND 0 0.0 ND
HPV-39 5 17.0 (5.5–39.7) 41.4 (38.7–44.1)* 5 35.2 (11.4–82) 26.2 (15.8–36.6)*
HPV-45 2 19.6 (2.3-ND) 39.6 (7.2–72.1) 1 125.0 (ND) 8 (ND)
HPV-51 4 33.3 (9-ND) ND 0 0.0 ND
HPV-52 0 0.0 ND 0 0.0 ND
HPV-56 2 20.4 (2.4-ND) 33 (17.1–48.8) 2 30.3 (3.6-ND) 27 (1.5–52.4)
HPV-58 0 0.0 ND 0 0.0 ND
HPV-59 4 19.5 (5.3–49.9) 42 (26.3–57.6) 1 15.2 (ND) 50 (ND)
HPV-68 2 11.6 (1.4-ND) 42 (32.2–58.8) 1 14.7 (ND) 32.6 (ND)
Type
Incident oral infections
Men who have sex with men (n = 333) Heterosexual men (n = 118)
No. Incidence rateb (95% CI) Mean timec (months) No. Incidence rateb (95% CI) Mean timec (months)
Low risk
HPV-6 8 0.9 (0.4–1.8) 54.2 (53.1–55.4) 2 0.6 (0.1–2) 53.2 (52.2–54.3)
HPV-11 1 0.1 (0.03–0.6) 55.8 (ND) 1 0.3 (ND) 53.6 (ND)
High risk
HPV-16 7 0.8 (0.3–1.7) 54.3 (53–55.4)* 7 2.2 (0.9–4.5) 50.6 (48.1–52.9)*
HPV-18 2 0.2 (0.02–0.8) 55.6 (55.1–56.1) 2 0.6 (0.1–2) 53.2 (52.2–54.3)
HPV-31 1 0.1 (ND) ND 0 0.0 ND
HPV-33 11 1.3 (0.6–2.2) 54.1 (53–55.2) 3 0.9 (0.2–2.5) 52.7 (51.2–54.2)
HPV-35 7 0.8 (0.3–1.6) ND 0 0.0 ND
HPV-39 3 0.3 (0.1–1) ND 0 0.0 ND
HPV-45 3 0.3 (0.1–1) ND 0 0.0 ND
HPV-51 7 0.8 (0.3–1.6) ND 0 0.0 ND
HPV-52 2 0.2 (0.03–0.8) 55.6 (55.1–56.1) 1 0.3 (ND) 53.6 (53–54.3)
HPV-56 2 0.2 (0.03–0.8) 55.6 (55.2–56.1) 1 0.3 (ND) 53.6 (53–54.3)
HPV-58 6 0.7 (0.2–1.5) ND 0 0.0 ND
HPV-59 8 0.9 (0.4–1.8) 54.7 (53.7–55.6) 3 0.9 (0.2–2.4) 52.6 (50.9–54.1)
HPV-68 0 0.0 ND 0 0.0 ND
ND, not determined; CI, conﬁdence intervals.
The unit of analysis was infections instead of individuals.
aClearance rate: number of cleared type-speciﬁc HPV infections per 1000 person-months.
bIncidence rate: number of new type-speciﬁc HPV infections per 1000 person-months.
cMean survival time.
*p <0.05: signiﬁcant differences between groups.
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in the follow-up. Similarly, a 1-year sampling interval may be
too long to determine incidence rates, as many incident
infections could have already been cleared by the time of the
next visit. Moreover, we cannot rule out that detection of
incident HPV is actually a reappearance of an existing infection.
In conclusion, the results of the present study could be
useful in highlighting the importance of regular clinical exam-
ination of the mouth of all HIV-infected patients because
heterosexual men presented a high prevalence and incidence
of oral HPV-16 infections in comparison to MSM. Thus, it
could be necessary to vaccinate young boys in order to
prevent dysplasia in the future.
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